Testimony from former CDC leadership highlighted differences with federal health officials on the process for reviewing and implementing vaccine policies.
Rural South Texas hospitals and physicians face mounting strain as rising uninsured rates and federal funding cuts threaten access to essential health care.
The DLL3-targeted bispecific T-cell engager agent tarlatamab demonstrated significant overall survival in combination with anti‒PD-L1 therapy of either atezolizumab or durvalumab as first-line mainten...
The first study to prospectively examine the impact of co-mutation biomarkers on sotorasib, a novel targeted therapy, for advanced KRAS G12C mutated NSCLC